The Global Drug sales of Zytiga stood at USD 1,770 Millions in 2022
The indicator recorded a historical decline (CAGR) of14% between 2019 to 2022 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Abiraterone acetate (Zytiga) is an antineoplastic agent. It is formulated as tablets and film coated tablets for oral route of administration.
Mechanism of Action
Abiraterone acetate is converted to abiraterone, an androgen biosynthesis inhibitor that inhibits 17 a-hydroxylase/C17, 20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 converts pregnenolone and progesterone to their 17a-hydroxy derivatives by 17a-hydroxylase activity and the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase activity. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals.
Zytiga Overview
Zytiga is marketed for the treatment of several indications in Oncology therapy area.
Zytiga is indicated in combination with prednisone for the treatment of metastatic prostate cancer (castration-resistant prostate cancer) in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in patients who have received prior chemotherapy containing docetaxel after failure of androgen deprivation therapy and in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer.
Zytiga was first approved in 2011 and is sold globally including the US, the UK, Australia, Germany, and Japan by Johnson & Johnson. Zytiga drug sales recorded a low-double digit Year on Year decline in 2022. Zytiga drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
2020: Does Immunotherapy Have a Future in Treating Prostate Cancer?
The treatment landscape for metastatic castrate-resistant prostate cancer (mCRPC) has shifted significantly in recent years. Chemotherapy, typically docetaxel or cabazitaxel, was the mainstay of mCRPC treatment until the development of drugs targeting the androgen receptor (AR). Johnson & Johnson’s Zytiga (abiraterone) and Astellas Pharma/Pfizer’s Xtandi (enzalutamide) are approved AR-antagonists that are now well-established as the standard of care for patients with mCRPC.
Immunotherapies have achieved significant milestones in a number of oncology indications—including melanoma, non-small cell lung cancer, and urothelial cancer. However, to date there has been little success within the mCRPC treatment landscape. The FDA approval of the personalized dendritic-cell-based vaccine, Dendreon’s Provenge (sipuleucel-T), for asymptomatic or minimally symptomatic mCRPC, is currently the only example of an immunotherapy approval for prostate cancer.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward